ClinicalTrials.gg
CompletedNCT00386191Updated Feb 24, 2010

Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment

A Phase 4 interventional study of clopidogrel (SR25990C) in Cerebral Infarction, sponsored by Sanofi. Completed at 1 site in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2010-02-24.

Sponsored by Sanofi · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,110
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Study summary

The primary objective is to compare the safety of clopidogrel 50mg and 75mg in cerebral infarction with respect to incidence of bleeding adverse events.

02

Conditions studied

  • Cerebral Infarction

Browse trials for

Keywords

  • Platelet Aggregation Inhibitors
  • Ischemic cerebrovascular disease
03

In context

Cerebral Infarction

219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.

This study's enrollment of 1,110 is above the median of 120 across 139 interventional studies indexed under Cerebral Infarction.

Browse Cerebral Infarction studies →

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with an episode of cerebral infarction (excluding cardiogenic cerebral thromboembolism) occurring at least 8 days prior to randomization and for whom the clinical course up to randomization is well-documented
  • Patients with a cerebral infarct confirmed by Computed Tomography or Magnetic Resonance Image
  • Body weight : > 50 kg

Exclusion criteria

Exclusion Criteria:

  • Patients with cardiogenic cerebral thromboembolism or disease that could precipitate cardiogenic cerebral thromboembolism, such as atrial fibrillation or valvular hear disease (including valve replacement)
  • Patients with occuring after the last episode of cerebral infarction
  • Patients with serious impairment that would hinder detection of new ischemic event
  • Patients with bleeding diathesis, coagulopathy, or hemorrhagic disease
  • Patients with history of intracranial hemorrhage
  • Patients with diabetic retinopathy
  • Hypertensive patients with a persistent increase of blood pressure.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,110 participants (actual)

Study arms

  • Experimental
    1

    50 mg

    Drug: clopidogrel (SR25990C)

  • Experimental
    2

    75 mg

    Drug: clopidogrel (SR25990C)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of bleeding adverse events

    Time frame: study period

Secondary outcomes

  1. Incidence of Serious Adverse Events, serious bleeding events, adverse events. Incidence of vascular events.

    Time frame: study period

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2006
First posted
Oct 11, 2006
Start
Sep 2006
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Last update
Feb 24, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00386191
Lead sponsor
Sanofi
First posted
Oct 11, 2006
Start date
Sep 2006
Primary completion
Dec 2008
Completion
Dec 2008
Last update
Feb 24, 2010

Study contacts

ICD CSD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion